Week 13 — Dec 7: Advanced Therapies & Capstone
(Lecture 12.) Large molecules were a population of one designed molecule. Advanced therapies push further: the “product” can be a virus, a strand of mRNA inside a lipid particle, or a single patient’s own cells — and the batch can be one.
The one idea
As a modality gets more complex and more personalised, characterisation gets harder, potency and identity move to the centre, and shelf life and batch size shrink — toward the point where you must release the product before all the analytical data is in. The analyst is often writing the method and the specification at the same time as the product exists.
The modalities and their control
| Modality | Made by | Characteristic analytical panel |
|---|---|---|
| Gene therapy (AAV, lentivirus) | Transient transfection or packaging cell lines; downstream chromatography | Vector genome titre (ddPCR), capsid identity (LC–MS), full/empty capsid ratio (AUC, charge-detection MS, AEX-HPLC, cryo-TEM), infectious titre (TCID50), aggregation (SEC-MALS, AUC), residual host-cell DNA / plasmid / helper functions, replication-competent virus, potency (transgene expression and function) |
| Cell therapy (CAR-T, TIL, allogeneic) | Isolate → activate → transduce → expand → formulate | Flow cytometry — identity and purity (%CD markers), viability, transduction efficiency; vector copy number (ddPCR); potency (cytotoxicity, cytokine release); rapid sterility and endotoxin; cell count and dose |
| mRNA / LNP | In-vitro transcription → LNP formulation | mRNA integrity (CE / on-chip electrophoresis), 5′ cap and poly(A) tail analysis (LC–MS), dsRNA impurity, encapsulation efficiency and mRNA content (RiboGreen), lipid identity and quantitation (HPLC-CAD, LC–MS), particle size / PDI (DLS), zeta potential, in-vitro expression potency |
| Oligonucleotides (ASO, siRNA) | Solid-phase synthesis | The bridge between small and large: IEX- and RP-HPLC, LC–MS for identity and sequence-related impurities (n−1, n+1, depurination), CE |
The recurring problems
- Potency, again — but worse. For a living or self-assembling product, potency is central and hard: a cell-therapy cytotoxicity assay or an AAV transgene-function assay carries large variability, and there is often no validated reference material.
- Identity of an assembly. When the “molecule” is a capsid carrying a genome, or a lipid particle carrying mRNA, identity is a set of orthogonal reads, not one spectrum.
- Release before the data. A 14-day sterility test does not fit a 3-day autologous product — hence rapid microbial methods (rapid sterility, ATP bioluminescence, NAT-based mycoplasma) and, sometimes, conditional release with follow-up.
- NGS as the new cross-cutting tool. Next-generation sequencing now does vector and plasmid identity/integrity, mRNA sequence confirmation, cell-line characterisation, and adventitious-agent detection — increasingly replacing in-vivo assays.
- The frameworks are still forming. FDA (OTP) and EMA (ATMP / CAT) guidance, and the accelerated pathways these products often use, are evolving faster than the compendia — so the Week 9 lesson about working on a moving regulatory target is sharpest here.
Where the analyst sits
With almost no reference materials, forming guidance, a batch size that can be one, and a clock that can be days, the analyst on an advanced therapy is doing the whole of Week 1 at once: choosing what to measure, developing the method, setting the specification, and defending all three — often before there is enough product to validate against. It is judgment under maximum uncertainty, and it is the STEAM “A” with the training wheels off. The refrain still holds, and matters more: science → evidence → reduced uncertainty → control → regulatory confidence → patient trust.
The capstone
The final session is an applied problem. In teams, take one modality and one scenario and work it end to end with the course’s tools:
- a comparability exercise after a manufacturing change (which methods, what acceptance criteria, what would force a clinical bridge?);
- an out-of-specification result and its investigation (root-cause tree, is the method or the product at fault?);
- a method transfer to a second site (what has to be demonstrated, what are the failure modes?);
- a specification-setting exercise for a new attribute (what data, what limits, justified how?).
Deliverable: a short analytical control strategy and a defence of it — the argument a regulator would have to follow.
Final paper presentations
Presentations run alongside the capstone (starting in Week 12 if numbers require). The paper is a critical analysis of an analytical method, technique, or problem of your choosing — argued the way the course has argued all term: what question does this measurement answer, what decision does it support, how is the result defended, and where does it fail?
Strong papers tend to:
- interrogate a real method, incident, or guideline rather than survey a topic;
- name the failure modes and the detectability of each (Week 2);
- connect the technique to a regulatory expectation and a patient consequence;
- say what they would do differently, and what evidence would change their conclusion.
Format
(Instructor: fill in — capstone team size and deliverable format; presentation length and Q&A; whether the written paper is due before or after the talk; grading split across paper, presentation, and capstone; peer-review expectations.)
Source note. Gene- and cell-therapy analytics follow USP ⟨1046⟩/⟨1047⟩, the emerging AAV and cell-therapy chapters, and FDA OTP and EMA ATMP guidance; mRNA-LNP follows the vaccine and mRNA-therapeutic analytical literature and WHO/regulatory guidance; oligonucleotides follow the OBP/USP oligonucleotide work. Rapid microbial methods follow USP ⟨1071⟩/⟨1223⟩ and Ph. Eur. 5.1.6 / 2.6.27. NGS for adventitious agents follows the evolving ICH/regulatory position. (Instructor: this field moves monthly — confirm the current guidance set; choose which two or three modalities to go deep on versus survey.)